Form 4: Jazz Pharmaceuticals Director Rick Winningham Reports Stock Transactions

Director Rick Winningham reports acquisition and disposal of Jazz Pharmaceuticals ordinary shares, including shares sold to cover tax obligations from vesting restricted stock units.

Summary

• Director Rick E Winningham reported transactions involving Jazz Pharmaceuticals plc ordinary shares.
• On August 2, 2024, Winningham acquired 3,731 ordinary shares at a price of $0.00.
• These shares were acquired as restricted stock units granted under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan, vesting fully on July 25, 2025.
• On August 6, 2024, Winningham disposed of 1,484 ordinary shares at a price of $111.35.
• These shares were sold to satisfy tax obligations related to the vesting of previously granted restricted stock units.
• Following these transactions, Winningham beneficially owns 12,691 ordinary shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are routine and related to equity compensation and tax obligations. No strong positive or negative implications.

Positives

• The acquisition of restricted stock units demonstrates continued alignment of the director's interests with the company's long-term performance.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the director's holdings.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales for tax purposes are common and don't necessarily indicate a negative outlook.

Comparison to Industry Standards

• Director stock ownership is a common practice across publicly traded companies, including pharmaceutical firms like Pfizer, Merck, and AbbVie.
• The vesting schedules and terms of restricted stock units are generally aligned with industry standards to incentivize long-term performance and retention.
• Sales to cover tax obligations are a standard part of equity compensation plans and are not unique to Jazz Pharmaceuticals.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the director's holdings, but the overall effect is likely negligible.

Key Dates